Genprex Bolsters Oncology Portfolio with Exclusive NYU Langone License for Reqorsa Gene Therapy in Mesothelioma Treatment

April 28, 2025

DENVER, Colo., Apr 28, 2025 (247marketnews.com)- Genprex (NASDAQ:GNPX) entered into an exclusive patent license agreement with NYU Langone Health for its drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), targeting mesothelioma. Co-owned by Genprex and NYU Langone, the licensed patent grants Genprex exclusivity, strengthening its oncology pipeline and underscoring its commitment to addressing unmet needs in aggressive cancers like malignant pleural mesothelioma (MPM).

Reqorsa: A Promising Approach for Mesothelioma

Reqorsa leverages the tumor suppressor gene TUSC2, which is downregulated in 84% of mesotheliomas, a cancer affecting the mesothelium, most commonly the pleura surrounding the lungs. With ~3,000 new U.S. cases and ~2,500 deaths annually, per the CDC, pleural mesothelioma carries a dire prognosis: an 18-month life expectancy and a 23% three-year survival rate with treatment. Reqorsa aims to restore TUSC2 expression, offering a novel therapeutic strategy.

Preclinical data presented by NYU Langone researchers at the 2024 EORTC-NCI-AACR Symposium showcased Reqorsa’s potential. In a study, four MPM cell lines and tert-transformed mesothelial LP9 cells were treated with Reqorsa or control liposomes for 48 hours. Analysis via RT-PCR, Western blot, and functional assays revealed:

  • Significant reduction in cell proliferation and invasion.
  • Marked increase in apoptosis across all MPM cell lines.
  • Potent tumor-suppressive activity, validating TUSC2 re-expression as a viable MPM treatment.
  • Strategic Collaboration and Expertise

Thomas Gallagher, Genprex’s Senior VP of Intellectual Property and Licensing, stated, “We are pleased to expand our robust oncology franchise, intellectual property portfolio and research program for REQORSA to continue exploring how it may serve as a therapeutic treatment for some of the most difficult to treat cancers and diseases. We believe REQORSA has the potential to treat mesothelioma, and this license agreement positions Genprex to expand its clinical development pipeline with future clinical studies that are within the scope of the licensed patent.”

The license agreement enhances Genprex’s partnership with NYU Langone, a leader in mesothelioma research. In 2024, Genprex formed its Mesothelioma Clinical Advisory Board, comprising four renowned researchers from top institutions to guide its preclinical program.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (GNPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.